Normative multiple-breath washout data in school-aged children corrected for sensor error

Footnotes

• Conflict of interest: A-C. Kentgens reports no conflicts of interest.

• Conflict of interest: P. Latzin reports grants from Vertex and Vifor paid to the institution, personal fees and honoraria paid to the institution from Vertex, Vifor and OM Pharma, personal fees for participation on a data safety monitoring board or advisory board from Santhera (DMC), and personal fees and fees paid to the institution from Polyphor, Vertex, OM pharma and Vifor, all outside the submitted work.

• Conflict of interest: P. Anagnostopoulou has nothing to disclose.

• Conflict of interest: R. Jensen has nothing to disclose.

• Conflict of interest: M. Stahl reports MBW over-reader service for Vertex Pharmaceuticals and a role as chairman of FGM, Secretary of Group CF ERS and Treasurer of GPP, outside the submitted work.

• Conflict of interest: A. Harper has nothing to disclose.

• Conflict of interest: S. Yammine reports a Swiss National Science Foundation grant 179905, outside the submitted work.

• Conflict of interest: R.E. Foong has nothing to disclose.

• Conflict of interest: G.L. Hall reports grant funding from the National Health and Medical Research Council of Australia and equipment loan from Niche Medical.

• Conflict of interest: F. Singer reports honoraria for lectures and presentations from Novartis Pharma Schweiz AG and Vertex Pharmaceuticals (CH) GmbH, outside the submitted work.

• Conflict of interest: S. Stanojevic reports MBW over-reader service for Vertex Pharmaceuticals and a role as chair of the Global Lung Function Initiative Network of the ERS, and the position of ATS Pulmonary Function Committee Co-Chair, outside the submitted work.

• Conflict of interest: M.A. Mall reports grants from the German Federal Ministry of Education and Research (grant number 82DZL004A1) and the Einstein Foundation Berlin (grant number EP-2017-393) during the conduct of this study, and personal fees for advisory board work, consultancy, and lectures from Boehringer Ingelheim and Vertex Pharmaceuticals, and patient recruitment fees for clinical trials from Boehringer Ingelheim and Vertex Pharmaceuticals (investigator-initiated study), outside the submitted work.

• Conflict of interest: F. Ratjen reports grants, consulting fees, or honorarium for CF related activities from Vertex, and reports to have acted as a consultant for CF related activities for Proteostasis, Bayer, Translate, Genentech, Boehringer Ingelheim and Calithera, outside the submitted work.

• Conflict of interest: K.A. Ramsey reports a grant from Vertex paid to the institution, and a role as co-chair of the ERS MBW GLI taskforce.

• Support statement: The work was supported by Swiss National Science Foundation Grants (K.A. Ramsey 168173; P. Latzin 182719). A-C. Kentgens is a recipient of the Swiss Government Excellence Scholarship from The Swiss Confederation. M.A. Mall reports grants from the German Federal Ministry of Education and Research (grant number 82DZL004A1) and the Einstein Foundation Berlin (grant number EP-2017-393). Funding information for this article has been deposited with the Crossref Funder Registry.